Candel Therapeutics Inc. Common Stock (CADL)
Stock · NASDAQ · Health Care
$8.18as of 10/16/2026
Price chart
Active signals
Resistance level
$9.59
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CADL Signal Track Record
How signals performed across all stocks →What CADL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -2.8% | 43% | September 11, 2026 |
| Bollinger Band Breakout | 26 | -5.3% | 42% | August 19, 2026 |
| Bollinger Band BreakdownActive now | 22 | +2.3% | 50% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -7.1% | 40% | February 11, 2026 |
| Any 20-session window (baseline) | -1.8% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 55
- Website
- www.candeltx.com/
Fundamentals
- 1-day range
- $8.13$8.92
- Market cap
- $775.20M
- P/E (trailing)
- —
- P/E (forward)
- -13.10
- EPS (trailing)
- $-1.41
- Dividend yield
- —
- Beta
- -0.28
- Avg. volume
- 1.17M
52-week range
$4.35$14
Next earnings: November 12, 2026 · EPS estimate $-0.31confirmed
How Candel Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 30, 2023 · via SEC EDGAR / Finnhub
Operating Income-$34.72M(-34722%)
Forecasts
8 analyst ratings
Buy 87%
Hold 13%
Sell 0%
1-year price forecast
High
$29
+254.5%
Median
$22.5
+175.1%
Low
$15
+83.4%
Candel Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CADLCandel Therapeutics Inc. Common Stock$8.19▼ 8.08%Market cap $775.20MP/E —$4.35$14
- AURAAura Biosciences Inc. Common Stock$6.1▼ 3.79%Market cap $798.53MP/E —$4.73$9.54
- DBVTDBV Technologies S.A. American Depositary Shares$9.05▼ 0.66%Market cap $813.58MP/E —$1.57$4.5
- SLDBSolid Biosciences Inc. Common Stock$5.53▼ 3.66%Market cap $857.50MP/E —$3.79$11.45
- ALLOAllogene Therapeutics Inc. Common Stock$1.31▼ 2.24%Market cap $679.95MP/E —$1.04$4.46
- AGMBAgomAb Therapeutics NV American Depositary Shares$8.28▼ 0.60%Market cap $664.85MP/E —$7.97$17.82
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CADL Candel Therapeutics Inc. Common Stock | $775.20M | — | $8.19 | ▼ 8.08% | $4.35$14 |
| AURA Aura Biosciences Inc. Common Stock | $798.53M | — | $6.1 | ▼ 3.79% | $4.73$9.54 |
| DBVT DBV Technologies S.A. American Depositary Shares | $813.58M | — | $9.05 | ▼ 0.66% | $1.57$4.5 |
| SLDB Solid Biosciences Inc. Common Stock | $857.50M | — | $5.53 | ▼ 3.66% | $3.79$11.45 |
| ALLO Allogene Therapeutics Inc. Common Stock | $679.95M | — | $1.31 | ▼ 2.24% | $1.04$4.46 |
| AGMB AgomAb Therapeutics NV American Depositary Shares | $664.85M | — | $8.28 | ▼ 0.60% | $7.97$17.82 |
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Candel Therapeutics to Present at the SITC 2026 Annual MeetingYahoo · 10/2/2026
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/1/2026
- Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICIYahoo · 10/1/2026
- Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.Benzinga · 10/1/2026
- CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’Yahoo · 9/30/2026
- Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate CancerYahoo · 9/30/2026
- Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026Yahoo · 9/30/2026
- Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate CancerBenzinga · 9/30/2026
- This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Mondaybenzinga · 9/21/2026
Insider Activity
Insider Actions →Acquired
513.8K
Disposed
317.7K
- Nicoletta Loggia · September 30, 2026 · Grant380 @ $8.68
- Paul B. Manning · September 30, 2026 · Grant2.2K @ $8.68
- Joseph C. Papa · September 30, 2026 · Grant1.3K @ $8.68
- Paul Peter Tak · September 11, 2026 · Sale59.4K @ $10.46
- Paul Peter Tak · September 10, 2026 · Option Exercise125.0K @ $1.55
- Paul Peter Tak · September 10, 2026 · Sale220.9K @ $11.5
- Zimmermann Martine · September 8, 2026 · Grant64.0K
- Seshu Tyagarajan · August 17, 2026 · Sale7.0K @ $12
- Sims Mark E. · July 6, 2026 · Grant285.0K
- Nicoletta Loggia · June 30, 2026 · Grant381 @ $8.64
- Paul B. Manning · June 30, 2026 · Grant2.2K @ $8.64
- Joseph C. Papa · June 30, 2026 · Grant1.3K @ $8.64
- Seshu Tyagarajan · June 29, 2026 · Sale7.0K @ $10.02
- Francesca Barone · June 29, 2026 · Sale23.4K @ $10.06
- Radhakrishnan Maha · June 23, 2026 · Grant32.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 43.13M
- Total value held
- $211.00M
- Institutional holders
- 110
Top holders this quarter
- Unknown10.99M
- Unknown6.42M
- Unknown3.50M
- Unknown3.11M
- Unknown2.90M
- Unknown2.89M
- Unknown2.46M
- Unknown1.13M
- Unknown1.06M
- Unknown1.04M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Candel Therapeutics Issues Inducement Grants to New Employees
Candel Therapeutics disclosed standard inducement grants awarded to newly hired employees. Under Nasdaq rules, such grants require public disclosure when given as incentives to attract talent. This is routine corporate governance news with no material impact on the company's operations or financial position. The grants align with standard market practices for biotechnology firms building their teams.
Candel Therapeutics Issues Inducement Grants to New Employees. Candel Therapeutics disclosed standard inducement grants awarded to newly hired employees. Under Nasdaq rules, such grants require public disclosure when given as incentives to attract talent. This is routine corporate governance news with no material impact on the company's operations or financial position. The grants align with standard market practices for biotechnology firms building their teams.